A 66/100 reflects a pattern of issues: pricing thats partially transparent but partially hidden, media logos with no links, pop-up pressure tactics, a cancellation process that left me uncertain, and zero disclaimers for medications not fully supported by science
Retatrutide does not yet have dedicated cardiovascular or renal outcome trials, though Phase 3 studies evaluating these endpoints are currently enrolling participants with expected completion in 2026
Cng thc ha hc ca GLP-1 l C165H264N50O55S2, khi lng mol khong 3,8 kDa v CAS 87805-34-3
GLP-1 Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Drug Candidates in Development for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom GLP-1 Drugs GLP-1 Drugs Distribution Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "GLP-1 Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target indication and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering
The danger of social-media sales and unregulated injections One of the most urgent issues in the weight-loss injection space is the explosion of unregulated, illicit online sales
Main Multi-Target GLP-1 Innovative Drug Pipelines Similarly, there are currently about 35 main pipelines for multi-target GLP-1 innovative drugs